Ameluz

WOBURN, Mass. — September 14, 2026 Biofrontera Inc. announced that the U.S. Food and Drug Administration (FDA) has approved...

WOBURN, Mass., Feb. 9, 2026 — Biofrontera Inc. announced positive top-line results from its multicenter Phase 3 clinical trial...